Overview

TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization

Status:
Completed

Trial end date:
2019-06-12

Target enrollment:

Participant gender:

Summary

The study is a single-centre, randomized, active controlled, open label clinical trial. The primary hypothesis is that ticagrelor will show superiority over clopidogrel immediately after CTO-PCI (chronic total occlusion - percutaneous coronary intervention)

Phase:

Phase 4

Details

Lead Sponsor:

Hospital Clinic of Barcelona

Collaborator:

AstraZeneca

Treatments:

Clopidogrel
Ticagrelor